Effect of Tadalafil 5mg Daily Treatment on Ejaculatory Times, Lower Urinary Tract Symptoms, and Erectile Function in Patients with Erectile Dysfunction
ABSTRACT
Objective
This study aims to investigate the effects of a daily dosage of 5mg tadalafil on ejaculatory times, erectile function, and lower urinary tract symptoms (LUTS) in men diagnosed with erectile dysfunction (ED).
Materials and Methods
A retrospective evaluation was conducted involving 60 patients diagnosed with ED. Outcomes were assessed using the International Index of Erectile Function questionnaire (IIEF-5), Intravaginal Ejaculatory Latency Time (IELT), and International Prostate Symptom Score (IPSS). Following three months of treatment with tadalafil at a dose of 5mg daily, patients were reassessed for changes in erectile function, ejaculatory latency, and LUTS. Additionally, fasting blood samples were collected to measure glucose, testosterone, and lipid profiles. Statistical analysis employed the independent-samples t-test to compare pre- and post-treatment scores.
Results
The average age of participants was 50.4 ± 7.9 years. Initial assessments showed mean IELT of 2.2 ± 1.4 minutes, IIEF-5 score of 9.5 ± 3.7, and IPSS of 14.1 ± 4.5. After three months of treatment, post-treatment measures were IELT 3.4 ± 1.9, IIEF-5 score 16.1 ± 4.7, and IPSS 10.4 ± 3.8. Statistically significant improvements were observed for IELT and IIEF-5 scores, while IPSS demonstrated a significant reduction (p < 0.01).
Conclusion
A daily administration of 5mg tadalafil is efficacious in enhancing erectile function and prolonging ejaculatory latency time, thus providing a safe option for treating both ED and LUTS.
Keywords: Tadalafil, Ejaculation, Erectile Dysfunction, Therapeutics
INTRODUCTION
Premature ejaculation (PE) is one of the most prevalent sexual dysfunctions affecting men, characterized by ejaculation occurring with minimal sexual stimulation. The prevalence rates of PE vary widely, ranging from 9% to 30%. In many cases, it coexists with erectile dysfunction (ED), creating a complex interplay that can exacerbate both conditions.
The relationship between PE and ED has been established in numerous studies, indicating that men suffering from PE may experience heightened anxiety and lower sexual satisfaction, which can lead to the development of ED. The dual impact of these conditions can significantly impair overall sexual health and quality of life.
Phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil, have been shown to improve erectile function, but their role in managing PE has gained interest. Tadalafil's long duration of action—up to 36 hours—may provide an effective therapeutic strategy for men dealing with both erectile and ejaculatory challenges.
MATERIALS AND METHODS
This study involved 60 men diagnosed with ED who were treated at a urology clinic. Participants were required to provide informed consent, and ethical approval was obtained for the study. Inclusion criteria included men aged 18 to 65, all in stable heterosexual relationships. Patients with a history of neurological disorders, chronic prostatitis, or current use of sexual enhancers were excluded to minimize confounding variables.
On baseline evaluation, each participant was assessed for erectile function using the IIEF-5 questionnaire and for ejaculatory latency through self-reported IELT, measured by their partners. LUTS were evaluated using the IPSS. Blood samples were taken after overnight fasting to assess metabolic parameters.
All participants received a regimen of 5mg tadalafil daily for three months. After this period, assessments were repeated to examine changes in erectile function, ejaculatory latency, and LUTS. Statistical analyses were performed using the SPSS software, focusing on comparisons between pre- and post-treatment scores.
RESULTS
The data collected revealed significant baseline characteristics as follows: the mean age was 50.4 ± 7.9 years. Baseline measurements for IELT were 2.2 ± 1.4 minutes, IIEF-5 9.5 ± 3.7, and IPSS 14.1 ± 4.5. After three months of treatment with daily tadalafil, patients demonstrated marked improvements with IELT increasing to 3.4 ± 1.9 minutes, IIEF-5 improving to 16.1 ± 4.7, and IPSS decreasing to 10.4 ± 3.8.
Statistical analysis confirmed that these changes were significant (p < 0.01), indicating that tadalafil not only enhanced erectile function but also contributed to longer ejaculatory latency, alongside alleviating urinary symptoms associated with BPH.
Adverse effects recorded included mild headaches and gastrointestinal discomfort in a small number of patients, which resolved without the need for intervention.
DISCUSSION
The findings of this investigation highlight the therapeutic benefits of tadalafil, reinforcing its role as an effective treatment for men with ED and concomitant PE. Given the established link between ED and psychological distress stemming from PE, addressing both conditions pharmacologically may enhance sexual satisfaction and improve overall quality of life.
Tadalafil’s mechanism of action relates to its inhibition of PDE5, leading to increased levels of cGMP, which promotes relaxation of smooth muscles and improved blood flow. This not only facilitates erections but may also impact ejaculatory control through modulation of the nervous system and vascular responses.
Further research is warranted to evaluate the long-term impacts of daily tadalafil use on ejaculatory function and to explore possible mechanisms that may contribute to its efficacy in managing PE. Such studies could help in refining treatment strategies for men facing these intertwined sexual health challenges.
CONCLUSION
In summary, the daily intake of 5mg tadalafil presents a promising therapeutic approach for men suffering from erectile dysfunction who also experience premature ejaculation. The ability to enhance erectile function and prolong ejaculatory latency can significantly contribute to improved sexual health and intimacy in affected individuals.
Consult Your Healthcare Provider
If you are considering tadalafil for the treatment of erectile dysfunction and associated ejaculatory issues, consult your healthcare provider for personalized advice and guidance tailored to your health condition.